Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 07, 2016 10:30 AM ET

Healthcare Equipment and Supplies

Company Overview of Ventana Medical Systems, Inc.

Company Overview

Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...

1910 East Innovation Park Drive

Tucson, AZ 85755

United States

Founded in 1985

952 Employees

Phone:

520-887-2155

Fax:

520-229-4207

Key Executives for Ventana Medical Systems, Inc.

Chief Executive Officer and Director
Age: 65
President
Age: 56
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Age: 69
Chief Financial Officer and Senior Vice President
Age: 49
Chief Operating Officer
Age: 54
Compensation as of Fiscal Year 2015.

Ventana Medical Systems, Inc. Key Developments

Ventana Medical Systems, Inc. Receives FDA Approval for ALK (D5F3) CDx Assay to Identify Lung Cancer Patients Eligible for Xalkori

Ventana Medical Systems, Inc. announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration (FDA) as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI® (crizotinib). The VENTANA ALK Assay was approved as a CE-IVD in Europe in 2012 and was approved by the Chinese Food and Drug Administration (CFDA) in 2013. With this US FDA Class III approval, ALK IHC testing is now widely accessible on VENTANA BenchMark1 immunohistochemistry (IHC) instruments globally, can be easily integrated into standard lab workflow and offers fast test results with a binary, straightforward scoring method. The test provides physicians and patients a fast and accurate method to identify ALK protein expression, and clinicians can be confident knowing that the company's FDA approval is based on data resulting from collaboration between Ventana and Pfizer. The company used the VENTANA ALK (D5F3) CDx assay and scoring method to retrospectively test patient samples from Pfizer-sponsored clinical trials and demonstrated that the test is effective in identifying patients with ALK-positive NSCLC who may benefit from treatment with XALKORI® (crizotinib). Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Halozyme Therapeutics, Inc., Ventana Medical Systems, Inc. Enter into Global Agreement to Collaboratively Develop Companion Diagnostic for Cancer Treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc. announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan (HA). HA is a glycosaminoglycan – a chain of natural sugars distributed throughout human tissue – that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic (IVD), under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. This pharma collaboration is one of many at Ventana, where the Companion Diagnostics team is developing patient stratifying diagnostic tools that can help identify those individuals who are most likely to benefit from specific treatments. Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Ventana Medical Systems, Inc. Enters into Master Collaboration Agreement with Astellas Pharma Inc

Ventana Medical Systems, Inc. announced it has entered into master collaboration agreement with Astellas Pharma Inc. to develop novel automated tissue diagnostics in support of therapeutic compounds in development. Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.

Similar Private Companies By Industry

Company Name Region
Medsign International Corporation United States
Tulsa Dental Products LLC United States
Vessix Vascular, Inc. United States
NovoPedics, Inc. United States
RhinoSystems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ventana Medical Systems, Inc., please visit www.ventana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.